Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Supernus Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Supernus Pharmaceuticals, Inc.’s stock price such as:

• Supernus Pharmaceuticals, Inc.’s current stock price and volume
• Why Supernus Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for SUPN from analysts
• SUPN’s stock price momentum as measured by its relative strength

About Supernus Pharmaceuticals, Inc. (SUPN)

Before we jump into Supernus Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Want to learn more about Supernus Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Supernus Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Supernus Pharmaceuticals, Inc.’s stock price was $44.630.

Supernus Pharmaceuticals, Inc. is down 2.15% from its previous closing price of $45.610.

During the last market session, Supernus Pharmaceuticals, Inc.’s stock traded between $44.350 and $45.670. Currently, there are approximately 57.65 million shares outstanding for Supernus Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Supernus Pharmaceuticals, Inc. Stock Price History

Supernus Pharmaceuticals, Inc.’s (SUPN) price is currently down 4.04% so far this month.

During the month of July, Supernus Pharmaceuticals, Inc.’s stock price has reached a high of $51.370 and a low of $44.350.

Over the last year, Supernus Pharmaceuticals, Inc. has hit prices as high as $59.680 and as low as $34.640. Year to date, Supernus Pharmaceuticals, Inc.’s stock is down 10.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Supernus Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Supernus Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Supernus Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Supernus Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Supernus Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Supernus Pharmaceuticals, Inc. (SUPN) by visiting AAII Stock Evaluator.

Relative Price Strength of Supernus Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Supernus Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 1.43%, which translates to a Momentum Score of 58 and is considered to be Average.

Want to learn more about how Supernus Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Supernus Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Supernus Pharmaceuticals, Inc.’s stock price is $44.630, which is down 2.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Supernus Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.